Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial
Edoardo Pennesi(Princess Máxima Center), C. Michel Zwaan(Hôpital Saint-Michel), Claudia Rössig(Klinik und Poliklinik für Kinder- und Jugendmedizin), Ingrid Øra(Karolinska University Hospital), Anna Nilsson(Karolinska University Hospital), Franco Locatelli(Bambino Gesù Children's Hospital), Susana Rives(Hospital Sant Joan de Déu Barcelona), Fanny Rialland(Hôpital Mère-Enfant), Vincent H. J. van der Velden(Erasmus MC), Gernot Engstler(St Anna Children's Hospital), Anneke C. J. Ammerlaan(Princess Máxima Center), Arnaud Petit(Sorbonne Université), Francisco Bautista(Princess Máxima Center), Carmelo Rizzari(Hôpital Saint-Michel), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Berna Beverloo(Erasmus MC), Erica Brivio(Princess Máxima Center), Bella Bielorai, Alba Rubio‐San‐Simón(Hospital del Niño), Bénedicte Bruno(Centre Hospitalier Universitaire de Lille), Benoît Brethon(Hôpital Saint-Louis), Barbara Sleight(Pfizer (United States)), Yilin Jiang(Princess Máxima Center)
Cited by 2
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738
B cell–helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen
|Nature Immunology|2011|724